Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today provided an overview of selected studies that will be presented at the 52 nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place from September 9 th to 12 th in San Francisco.
The studies focus on the company’s lead investigational antibiotics, CXA-201 and CB-315, basic science research as well as the marketed antibiotic, CUBICIN® (daptomycin for injection).
“The breadth of presentations at ICAAC shows how we are advancing science to not only inform the appropriate use of CUBICIN but also to discover and develop new antibiotics for serious and potentially life-threatening infections,” said Steve Gilman, PhD, Chief Scientific Officer at Cubist Pharmaceuticals. “We’re excited that our lead pipeline antibiotics are now in pivotal Phase 3 trials and we hope to one day make them available to doctors and patients who deal with the challenge of emerging resistant infections.”
A list of selected presentations can be found on the company’s website. Key highlights include:CXA-201 (Ceftolozane/tazobactam) CXA-201, a novel cephalosporin in combination with tazobactam, is in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms, particularly Pseudomonas aeruginosa and those in the Enterobacteriaceae family. This year at ICAAC, six studies on CXA-201 will be presented. In one important study, CXA-201 showed greater potency than currently available anti- Pseudomonas aeruginosa cephalosporins (ceftazidime and cefepime) and piperacillin/tazobactam when tested against Pseudomonas aeruginosa and Enterobacteriaceae strains from hospitals in the United States. Activity of the Novel Antimicrobial Ceftolozane/Tazobactam Tested Against Contemporary Clinical Strains from USA Hospitals (2011) (Abstract E-199) Sunday, September 9, 2012, 11:30 a.m. - 1:30 p.m. PDT, Halls A-C. CB-315 CB-315, a novel oral antibiotic, is in development for the treatment for Clostridium difficile-associated diarrhea, or CDAD. Clostridium difficile causes diarrhea linked to 14,000 American deaths each year. This year the company initiated pivotal Phase 3 studies of CB-315, and in vitro data at ICAAC will show that Clostridium difficile is more susceptible to CB-315 than to other antibiotics like vancomycin and moxifloxacin. Susceptibilities of Clostridium difficile to CB-183,315 and Comparators (Abstract E-807) Monday, September 10, 2012, 11:15 a.m. - 1:15 p.m. PDT, Halls A-C. Discovery Biology Several abstracts on basic science and drug discovery efforts will be presented at the meeting. One of these focuses on CB-027, which is a novel broad spectrum cephalosporin with potent in vitro activities against both Gram-positive and Gram-negative bacteria. This includes methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. In this animal study, CB-027 showed potent in vivo activity against several drug-resistant strains, including MRSA, ceftazidime-resistant Pseudomonas aeruginosa and Klebsiella pneumonia. In vivo Efficacy of CB-027 against Methicillin-Resistant Staphylococcus aureus , and Ceftazidime-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae Infections in Mice (Abstract F-846) Monday, September 10, 2012, 11:15 a.m. - 1:15 p.m. PDT, Halls A-C. CUBICIN (daptomycin for injection) More than 30 scientific abstracts at ICAAC feature data on daptomycin. Importantly in an oral presentation, new data will show that early use of daptomycin significantly lowers rates of clinical failure, including both 90-day mortality and microbiological failure compared to vancomycin for infections caused by certain strains (VAN MIC > 1 mg/L) of MRSA.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV